New year, new tax rates. How did the world’s biggest drug­mak­ers fare?

Bio­phar­ma is burst­ing with re­ports this month of how Trumpian tax breaks will af­fect the in­dus­try’s biggest play­ers, with Ab­b­Vie’s $AB­BV jaw-drop­ping 50% rate slash win­ning the award for most no­table head­line. Big Phar­ma joined the pa­rade short­ly there­after, each tout­ing tax rate pro­jec­tions that equate to big mon­ey on the books for 2018.

We col­lect­ed re­ports from 13 of the biggest drug­mak­ers af­fect­ed by the US cor­po­rate tax cut — all with rev­enues in the dou­ble-dig­it bil­lions — to gauge the av­er­age im­pact of the new law on Big Phar­ma (full list be­low).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER